

ABSTRACT

The present invention concerns a method of
treating LBP-mediated LPS-induced myeloid cell
activation comprising administering a therapeutically
effective amount of an anti-LBP monoclonal antibody
molecule. A therapeutic composition comprising anti-
LBP antibody molecules in a pharmaceutically
acceptable excipient is also contemplated.